Evonile Pharma Limited
NSE: NOVARTIND · Pharmaceuticals
Snapshot
Unlock Evonile Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Novartis India Limited is a healthcare company that markets a diverse portfolio of pharmaceutical and generic products. Its therapeutic focus spans bone and pain management, gynecology, neurosciences, and transplantation immunology.
Business Model
The company generates revenue through the commercialisation of established pharmaceutical brands and generic products within the Indian market. It operates as a subsidiary of the global pharmaceutical giant Novartis AG, leveraging its parent's established brand equity.
- Incorporation Year:1947
Growth Outlook
Growth is primarily driven by the sustained demand for its core therapeutic brands such as Voveran, Tegrital, and Exelon. The company continues to focus on its established portfolio in the Indian healthcare sector.
Key Risks
- Regulatory Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can compress profit margins.
- Generic Competition. The pharmaceutical sector in India is highly competitive, with numerous local manufacturers offering low-cost generic alternatives to established brands.
- Parent Company Dependency. As a subsidiary of Novartis AG, the company's strategic direction and product pipeline are heavily influenced by the global parent's corporate priorities.
- Supply Chain and Quality Compliance. Strict adherence to manufacturing standards and supply chain integrity is essential to avoid regulatory sanctions and reputational damage.
Start your research today
Unlock AI insights, financials, peers and live data on Evonile Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹371 Cr
TTM · standalone
NET PROFIT
₹98 Cr
TTM · standalone
EPS
₹39.61
TTM · standalone
RETURN ON EQUITY
12.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.7%
TTM · standalone
P/E
43.5×
Q1 FY27 · standalone
EV/EBITDA
30.1x
Q1 FY27 · standalone
EBITDA MARGIN
37.4%
TTM · standalone
NET PROFIT MARGIN
31.0%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Evonile Pharma LimitedNOVARTIND | ₹4,233 Cr | 43.5× | 30.15 | 5.4% | 37.4% | 12.2% | 16.7% | +99.8% |
Gufic Biosciences LimitedGUFICBIO | ₹4,301 Cr | 58.6× | 27.72 | 16.7% | 17.0% | 11.6% | 16.9% | +31.2% |
RPG Life Sciences LimitedRPGLIFE | ₹4,298 Cr | 38.7× | 23.25 | — | 23.7% | 16.2% | 16.9% | +5.5% |
Zota Health Care LimitedZOTA | ₹4,218 Cr | -38.8× | 365.42 | 78.9% | 1.9% | -22.7% | -14.6% | -21.9% |
Jeena Sikho Lifecare LimitedJSLL | ₹4,185 Cr | 17.7× | 10.84 | — | 45.2% | 50.6% | 58.2% | -57.0% |
Aarti Drugs LimitedAARTIDRUGS | ₹4,160 Cr | 21.8× | 14.06 | — | 12.6% | 13.1% | 14.5% | -9.5% |
As of Q1 FY27
Financials
Evonile Pharma Limited
NSE: NOVARTIND · Pharmaceuticals
Snapshot
Unlock Evonile Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Novartis India Limited is a healthcare company that markets a diverse portfolio of pharmaceutical and generic products. Its therapeutic focus spans bone and pain management, gynecology, neurosciences, and transplantation immunology.
Business Model
The company generates revenue through the commercialisation of established pharmaceutical brands and generic products within the Indian market. It operates as a subsidiary of the global pharmaceutical giant Novartis AG, leveraging its parent's established brand equity.
- Incorporation Year:1947
Growth Outlook
Growth is primarily driven by the sustained demand for its core therapeutic brands such as Voveran, Tegrital, and Exelon. The company continues to focus on its established portfolio in the Indian healthcare sector.
Key Risks
- Regulatory Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can compress profit margins.
- Generic Competition. The pharmaceutical sector in India is highly competitive, with numerous local manufacturers offering low-cost generic alternatives to established brands.
- Parent Company Dependency. As a subsidiary of Novartis AG, the company's strategic direction and product pipeline are heavily influenced by the global parent's corporate priorities.
- Supply Chain and Quality Compliance. Strict adherence to manufacturing standards and supply chain integrity is essential to avoid regulatory sanctions and reputational damage.
Start your research today
Unlock AI insights, financials, peers and live data on Evonile Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹371 Cr
TTM · standalone
NET PROFIT
₹98 Cr
TTM · standalone
EPS
₹39.61
TTM · standalone
RETURN ON EQUITY
12.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.7%
TTM · standalone
P/E
43.5x
Q1 FY27 · standalone
EV/EBITDA
30.1x
Q1 FY27 · standalone
EBITDA MARGIN
37.4%
TTM · standalone
NET PROFIT MARGIN
31.0%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27